HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Update on cost-effectiveness of a 12-dose regimen for latent tuberculous infection at new rifapentine prices.

AuthorsDylan Shepardson, William R MacKenzie
JournalThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease (Int J Tuberc Lung Dis) Vol. 18 Issue 6 Pg. 751 (Jun 2014) ISSN: 1815-7920 [Electronic] France
PMID24903950 (Publication Type: Letter, Comment)
Chemical References
  • Antitubercular Agents
  • Isoniazid
  • Rifampin
Topics
  • Antitubercular Agents (administration & dosage, economics)
  • Drug Costs
  • Humans
  • Isoniazid (administration & dosage, economics)
  • Latent Tuberculosis (drug therapy, economics)
  • Rifampin (analogs & derivatives)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: